The Role of Sirolimus in Preventing Functional Decline in Older Adults
NCT05237687
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Aging is associated with progressive impairment of tissue and organ function, resulting in increased susceptibility to chronic disease, frailty and disability. Currently there are limited treatment options to alter this inevitable process. The proposed work has the potential to identify a new therapeutic intervention to decrease aging-related degenerative processes. Rapamycin or sirolimus is a macrocyclic immunosuppressive drug that inhibits the mammalian target of rapamycin (mTOR).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Aging
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 65 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Irina Timofte
- Last updated on ClinicalTrials.gov
- June 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- UT Southwestern Medical Center · Dallas, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.